Anti-Obesity Drugs - Global Strategic Business Report

Description:
This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 33 companies including many key and niche players such as:
- Arena Pharmaceuticals, Inc.
- GlaxoSmithKline Plc
- Novo Nordisk
- Orexigen Therapeutics, Inc.
- Rhythm Pharmaceuticals

Contents:
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
   Study Reliability and Reporting Limitations
   Disclaimers
   Data Interpretation & Reporting Level
   Quantitative Techniques & Analytics
   Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY
   1. INDUSTRY OVERVIEW
      Anti-Obesity Therapeutics
      A Significantly Underserved Market
      Obesity: An Unmet Medical Need
      Currently Available Drugs
      List of Currently Available Drugs for the Treatment of Obesity
      The United States
      The Largest Obesity and Anti-Obesity Market
      Europe
      A Market with Vast Potential
      Emerging Economies to Lead Growth
      Table 1: Global Obesity Prevalence (2013): Percentage Share Breakdown of Obese Population by Leading Countries (includes corresponding Graph/Chart)

   2. COMPETITIVE SCENARIO
      Drug Withdrawals Alter Competition Metrics
      Unfavorable Reimbursement Levels Hamper Growth
      New Entrants to Induce Competition
      Anti-Obesity Drugs Under Pipeline

   3. MARKET TRENDS, DRIVERS AND CHALLENGES
      Alarming Rise in Global Obesity Levels
      The Major Growth Factor
      Table 2: Classification of BMI
      Table 3: Overweight and Obese Population (Millions) for 2013 in Select Geographic Regions (includes
Table 4: Global Obesity Levels by Leading Countries and Others (2013): Percentage Breakdown of Obese Population for the United States, India, China, Mexico, the United Kingdom, Germany, Spain, Australia, Canada, Japan, Greece, South Korea, Portugal, Slovakia, New Zealand, Finland, Switzerland, Ireland, and Others (includes corresponding Graph/Chart)

Table 5: Abdominal Obesity Prevalence (%) by Region and Gender (includes corresponding Graph/Chart)

Growth Emphasis on Metabolism
New Research Aids in Discovery of Novel Drugs
Cyclic Guanosine Monophosphate Signaling
The Future of Anti-Obesity Pharmacotherapy?

Childhood Obesity
A Market with Unmet Needs
Online Drug Stores Boost Sales
Barriers to Development of Effective Drugs
Regulatory Additions
A Barrier to Entry?
High Drug Development Costs
A Major Setback
Weight Loss Alternatives
A Market Dampener
Short Treatment Duration
A Major Limiting Factor for Market Growth
Product Labelling Could Deter Treatment Continuation

4. SELECT PIPELINE DRUG CANDIDATES

Orexigen Completes Phase 3 Clinical Trials for NB32
Empatic™ Completes Phase II
Zafgen Completes Phase II Trial of Beloranib
Novo Nordisk Completes Phase III trial of Liraglutide
Rhythm Pharmaceuticals Commences Phase 2 Trials for RM 493
University of Michigan to Commence Trial of Amlexanox in Treating Obesity

5. SELECT SCIENTIFIC BREAKTHROUGHS

Study Links PAR2 Protein Amount to Obesity
Scientists at Cambridge University Discover Hunger Gene
Ghrelin Hormone Linked to Hunger and Obesity

6. OBESITY AN INTRODUCTION

Diagnosis of Obesity
BMI Calculation and Classification
Waist Circumference and BMI
Types of Obesity
Monogenic Obesity
Polygenic Obesity
Causes of Obesity
Unhealthy Eating Habits
Environmental and Genetic Factors
Sedentary Lifestyle
Alcohol Intake
Childhood Obesity
Psychological Factors
Pregnancy
Hormonal Disorders
Drugs
Aging
Risks Associated with Obesity

7. OBESITY TREATMENT

Dietary Therapy
Exercise Therapy
Behavior Therapy
Pharmacotherapy
Weight Loss Surgery
Invasive vis-à-vis Non-invasive Procedures
A Brief Review of Select Invasive Procedures
Bariatric Surgery
Laparoscopic Adjustable Gastric Banding (LAGB)
Vertical Banded Gastroplasty (VBG)
Roux-en-Y Gastric Bypass Procedure (RYGB)
Lap-Band Procedure
Gastric Band Procedure
Gastric Bypass Procedure
Doudenal Switch
Prescription Drugs vis-à-vis Non-Prescription Drugs
Table 6: Obesity Treatment Options and Corresponding Success Rate

8. ANTI-OBESITY DRUGS AN INSIGHT

Introduction
Mechanism of Action
Review of Available Prescription Anti-Obesity Drugs
Phentermine
Orlistat
Belviq (Lorcaserin)
Phentermine/Topiramate Cocktail
Table 7: Global Anti-obesity Prescription Drugs Market (2012): Percentage Share Breakdown of Prescriptions by Physician Practices
Primary Care Physicians (PCP), Internal Medicine, Obstetrics/Gynecology, Endocrinology/Diabetes, Psychiatry/Neurology, Cardiology and Others (includes corresponding Graph/Chart)

9. RECENT INDUSTRY ACTIVITY

Novo Nordisk to Launch Anti-Obesity Drug in Mexico
Orexigen Optimistic of FDA Approval for Contrave
Arena Extends Belviq Distribution Agreement with Eisai
Sorrento Partners Scripps Research
MedImmune Partners NGM Biopharmaceuticals to Develop Anti-Obesity Therapy
Arena Launches Belviq
Kitozyme Signs Deal with Corona
GSK and Vanderbilt Sign Agreement for New Anti-Obesity Drug
ScinoPharm Signs Agreement for Contract Manufacturing
Vivus Launches Qsymia
ScinoPharm Enters Supply Deal with Vivus

10. FOCUS ON SELECT PLAYERS

Arena Pharmaceuticals, Inc. (US)
F. HOFFMANN-LA ROCHE LTD. (Switzerland)
GlaxoSmithKline Plc. (UK)
Novo Nordisk (Denmark)
Orexigen Therapeutics, Inc. (US)
Rhythm Pharmaceuticals (US)
VIVUS, Inc. (US)
Zafgen Inc. (US)

11. GLOBAL MARKET PERSPECTIVE

Table 8: World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (Excl. Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 9: World Historic Review for Anti-Obesity Drugs by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (Excl. Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

Table 10: World 15-Year Perspective for Anti-Obesity Drugs by Geographic Region
Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (Excl. Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis

Table 11: US Weight Loss Market by Major Product Segment (2013): Percentage Share Breakdown of Revenues for Diet Drinks, Health Clubs, Bariatric Surgery, Diet Foods, Artificial Sweeteners, Weight Loss Centers, Medically Supervised Programs, Meal Replacements & Appetite Suppressants, Prescription Drugs, Low Calorie Diet Programs, and Others (includes corresponding Graph/Chart)

Competitive Scenario

Obesity Catching Them Young

Table 12: US Childhood Obesity by Age-Group (2013): Percentage of Obese Population (includes corresponding Graph/Chart)

Penetration of Anti-Obesity Drugs Remains Poor

Key Statistics

Table 13: US Obesity Rates by Ethnicity for Men & Women: 2013 (includes corresponding Graph/Chart)

Table 14: Proportion (%) of Obesity in the US Overweight Population by Age Group (includes corresponding Graph/Chart)

Table 15: Obesity Prevalence in US Adults by Type (2013) (includes corresponding Graph/Chart)

Table 16: US Obesity Prevalence by Age-group: 2013 (includes corresponding Graph/Chart)

Table 17: US Obesity Prevalence by Annual Income Level (%): 2013 (includes corresponding Graph/Chart)

State-wise Stats

Table 18: US Obesity Prevalence by Top Cities (% of Total Population): 2013 (includes corresponding Graph/Chart)

Table 19: US Prevalence of Obesity by Top States (% of Total Population): 2013 (includes corresponding Graph/Chart)

Reimbursement Scenario

Regulatory Environment

High Development Costs

A High Entry Barrier for Drug Makers

Lack of Overall efficacy and outcomes data

A Dampener

Obesity and Related Ailments: Burden on Societal and Economic Costs

Product Launches

Strategic Corporate Developments

Select Key Players

B. Market Analytics

Table 20: The US Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 21: The US Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

2. CANADA

Market Analysis

Table 22: Canadian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 23: Canadian Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

3. JAPAN

Market Analysis

Table 24: Japanese Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 25: Japanese Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
4. EUROPE

A. Market Analysis

Europe
an Opportune Market for Chronic Weight Management Drugs

Prevalence of Obesity in Europe

Table 26: Obese and Overweight & Obese Population in the European Union (2013): Percentage Share Breakdown by Age Group (includes corresponding Graph/Chart)

Table 27: Select EU Member Countries Ranked by Obesity Rates (2013): Percentage Share of Domestic Obese Population in Global Obese Population (includes corresponding Graph/Chart)

Table 28: Obesity Prevalence in Select EU Countries (2013) by Gender (%) (includes corresponding Graph/Chart)

B. Market Analytics

Table 29: European Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region/Country
France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 30: European Historic Review for Anti-Obesity Drugs by Geographic Region/Country
France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

Table 31: European 15-Year Perspective for Anti-Obesity Drugs by Geographic Region/Country
Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

4a. FRANCE

A. Market Analysis
Changing Lifestyle Alters Health Profile

B. Market Analytics

Table 32: French Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 33: French Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4b. GERMANY

A. Market Analysis
The Largest Anti-Obesity Market in Europe

B. Market Analytics

Table 34: German Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 35: German Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4c. ITALY

Market Analysis

Table 36: Italian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 37: Italian Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

A. Market Analysis
Anti-Obesity Drugs
the Need of the Hour as NHS Firefights Rising Peril of Obesity

GlaxoSmithKline Plc
A Key Player

B. Market Analytics

Table 38: The UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 39: The UK Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4e. REST OF EUROPE

A. Market Analysis

Review of Select Markets
Spain
Belgium
The Netherlands
Finland
Sweden
Strategic Corporate Development
Key Players
B. Market Analytics
Table 40: Rest of European Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 41: Rest of European Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis
Brief Review of Select Countries
Australia
Table 42: Australian Obesity & Overweight Prevalence (2013): Percentage Share Breakdown of Population for Obese/Overweight, Healthy Weight and Underweight Categories (includes corresponding Graph/Chart)
Historic Perspective:
Table 43: Prevalence Rate (%) of Overweight/Obese Students in Australia (includes corresponding Graph/Chart)
China
India
Korea
Use of Diet Pills Lack Proper Monitoring
New Zealand
Strategic Corporate Developments
B. Market Analytics
Table 44: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 45: Asia-Pacific Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

6. LATIN AMERICA

A. Market Analysis
Mexico
A Review
B. Market Analytics
Table 46: Latin American Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 47: Latin American Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

7. REST OF WORLD

Market Analysis
Table 48: Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 49: Rest of World Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 33 (including Divisions/Subsidiaries 34)
The United States (14)
Japan (4)
Europe (8)
The United Kingdom (3)
Rest of Europe (5)
Asia-Pacific (Excluding Japan) (8)
Ordering:  
Order Online - http://www.researchandmarkets.com/reports/834997/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,  
Guinness Centre,  
Taylors Lane,  
Dublin 8,  
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Anti-Obesity Drugs - Global Strategic Business Report</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/834997/">http://www.researchandmarkets.com/reports/834997/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCBR1LL1</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 4950</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>USD 6930</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 10 Users:</td>
<td>USD 9405</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 15 Users:</td>
<td>USD 11880</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address:</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World